Title: Ardeparin
Literature References: Low molecular weight heparin prepared by the depolymerization of porcine mucosal heparin in the presence of peroxides. Average mol wt 5500-6500 daltons. Manufacturing process: F. Fussi, US 4281108 (1981 to Hepar Ind.). Description of properties and activity: idem et al., Dev. Biochem. 12, 535 (1981). Clinical pharmacokinetics: S. Troy et al., J. Clin. Pharmacol. 35, 1194 (1995). Clinical trials in prevention of postoperative venous thrombosis: M. N. Levine et al., Arch. Intern. Med. 156, 851 (1996); J. A. Heit et al., Thromb. Haemostasis 77, 32 (1997).
Derivative Type: Sodium salt
Manufacturers' Codes: WY-90493-RD
Trademarks: Normiflo (Wyeth-Ayerst)
Properties: LD50 in mice, rats (mg/kg): >3000, >2000 i.p.; >1000, 354 ±30 i.v.; >6000, >6000 orally (Fussi et al.).
Toxicity data: LD50 in mice, rats (mg/kg): >3000, >2000 i.p.; >1000, 354 ±30 i.v.; >6000, >6000 orally (Fussi et al.)
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.
Areca Arecaidine Arecoline Argatroban Arginine Glutamate

Ardeparin sodium
Systematic (IUPAC) name
Clinical data
AHFS/ Multum Consumer Information
Pregnancy cat. C (US)
Legal status Withdrawn
Pharmacokinetic data
Bioavailability 92%
ATC code None
DrugBank DB00407
Chemical data
Formula (C26H40N2O36S5)n
Mol. mass 5500–6500 Daltons (average)
 N (what is this?)  (verify)

Ardeparin (trade name Normiflo) is an anticoagulant. It was used for the prevention of deep vein thrombosis, but was withdrawn form the US market in 2000.[1]